Following positive Phase IIb trial results, RH5.1/Matrix-M has the potential to be the first blood-stage malaria vaccine brought to market.

Alumis has revealed encouraging results from a Phase I clinical trial of tyrosine kinase 2 (TYK2), A-005, in healthy subjects.

Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.

Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma delta CAR T-cell therapy for treating ccRCC.

Sorriso Pharmaceuticals announced that it is looking to move to Phase II after its ulcerative colitis treatment saw success over placebo.

The WHO’s guidance provides direction on diversity and how to include patients who are pregnant, lactating and from low-middle income countries.

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

As of 2005, 83% of babies with critical congenital heart defects were expected to live past one year, up from 67% in 1993.

Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic NAMPT inhibitor, RPT1G, for cancers.

APAC was followed by North America and then Europe for percentage of clinical trials in Parkinson’s disease. Credit: AtlasStudio / Shutterstock. The Asia-Pacific (APAC) region is leading in the ...

PBGENE-HBV specifically targets the hepatitis B viral genome. Credit: Jarun Ontakrai/Shutterstock. Precision Biosciences has gained the approval of its clinical trial application (CTA) in Hong Kong to ...

Results from the company’s trial examining the drug in 586 patients with early-stage Parkinson’s disease found that the drug was able to show some success in its primary endpoint. Credit: Shutterstock ...